Login / Signup
SCD and MTHFD2 inhibitors for high-risk acute myeloid leukaemia patients, as suggested by ELN2017-pathway association.
Han Sun Kim
Doyeon Kim
Jiwoo Kim
Sunghyouk Park
Arvie Camille V de Guzman
Published in:
Clinical and translational medicine (2023)
Keyphrases
</>
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
liver failure
peritoneal dialysis
bone marrow
dendritic cells
acute myeloid leukemia
immune response
drug induced
intensive care unit
hepatitis b virus
extracorporeal membrane oxygenation